Cadherins, contact normalization, and targeting podoplanin to treat oral cancer
钙粘蛋白、接触正常化和靶向平足蛋白治疗口腔癌
基本信息
- 批准号:10437217
- 负责人:
- 金额:$ 48.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-15 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Adherens JunctionAntibodiesBasic ScienceBiological MarkersCadherinsCancer EtiologyCancer PatientCancer SurvivorCell Culture TechniquesCell SurvivalCellsCellular MorphologyCellular biologyClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsContractsCytotoxic agentEnvironmentFDA approvedFibroblastsFutureGenesGrowthHumanImmuneImmune responseInfiltrationInflammationInstitutionInstitutional Review BoardsInstructionLectinLesionLeukoplakiaMaackia amurensisMalignant - descriptorMalignant Epithelial CellMalignant NeoplasmsMediatingMedical StudentsMolecular BiologyMorphologyNormal CellOncogenicOralPatientsPersonsPhasePhase I Clinical TrialsPhysiciansProcessQuality of lifeReagentResearchScientistSeedsSideSignal TransductionSurvival RateSurvivorsTechnologyTestingTimeVascularizationWNT Signaling PathwayWorkanti-cancerbasecancer cellcell growthcell motilitycell transformationchemotherapyclinical translationena proteinestablished cell linegenetic corepressorgraduate studenthomologous recombinationimmune cell checkpointsmalignant mouth neoplasmmammarymortalitymouth squamous cell carcinomamucin receptorneoplastic celloral lesionpodoplaninpreclinical studypremalignantpreventrefractory cancerside effectsrc-Family Kinasestranscriptometumortumor growthtumor progression
项目摘要
Summary
Oral cancer kills over 8,000 people in the USA and 120,000 people worldwide every year. In addition to
this mortality, oral cancer survivors suffer from permanent sequelae and decreased quality of life. Over 90% of
oral cancers are caused by oral squamous cell carcinoma (OSCC).
This project is based on the premise that nontransformed cells can control the growth of neighboring
transformed cells by contact normalization. Direct contact between transformed and nontransformed cells is
required for this process. However, junctions responsible for contact normalization, and gene products that
enable cancer cells to overcome this form of growth control, have not been defined. We found that contact
normalization suppresses expression of the transmembrane mucin receptor podoplanin (PDPN) downstream
of oncogenic Src tyrosine kinase activity.
Many cancer cells, including OSCCs, express PDPN to promote cancer progression. Precancerous oral
lesions (e.g. leukoplakia) that express high levels of PDPN are several times more likely to become cancers
than lesions that do not express PDPN. In addition, PDPN has been identified as an immune cell checkpoint
corepressor. Indeed, PDPN has emerged as a functionally relevant biomarker and chemotherapeutic target
that can be used to detect and treat oral cancer. Our rationale is based on the fact that cadherin junctions are
often disrupted between transformed cells, while PDPN expression is enhanced.
PDPN antibodies and Maackia amurensis seed lectin (MASL) efficiently target PDPN to decrease
OSCC cell motility and viability. Moreover, MASL is nontoxic and can be administered orally to inhibit tumor
growth and vascularization without notable side effects in preclinical studies. We hypothesize that cadherins
mediate contact normalization to suppress PDPN expression, and PDPN can be utilized as a functionally
relevant chemotherapeutic target to synergistically inhibit tumor cell growth and augment anticancer immune
response. We propose 3 Specific Aims to test this hypothesis.
In Aim 1, we will determine if cadherins are needed for nontransformed cells to normalize morphology,
growth, motility, Wnt signaling, and PDPN expression of adjacent Src transformed and OSCC cells. In Aim 2,
we will determine if PDPN signaling enables Src transformed fibroblasts and OSCC cells to override growth
control by neighboring nontransformed cells. In Aim 3, we will determine if MASL can target PDPN to augment
host immune response in concert with its ability to inhibit OSCC cell growth in an FDA approved Phase 1
human clinical trial on oral cancer patients.
This project will expose graduate and medical students to basic research in molecular and cell biology
to elucidate fundamental mechanisms behind contact normalization. This work will enhance our abilities to
detect, prevent, and treat oral cancer, as well as other cancers that are driven by PDPN signaling.
总结
口腔癌每年在美国造成8,000多人死亡,在全世界造成120,000人死亡。除了
这种死亡率,口腔癌幸存者遭受永久性后遗症和生活质量下降。超过90%的
口腔癌由口腔鳞状细胞癌(OSCC)引起。
这个项目是基于这样一个前提,即未转化的细胞可以控制邻近细胞的生长。
通过接触归一化转化细胞。转化细胞和非转化细胞之间的直接接触是
此过程所需的。然而,负责接触正常化的连接和基因产物,
使癌细胞能够克服这种形式的生长控制,还没有被定义。我们找到那个接头人了
正常化抑制跨膜粘蛋白受体podoplanin(PDPN)下游的表达
致癌Src酪氨酸激酶活性。
许多癌细胞,包括OSCC,表达PDPN以促进癌症进展。口腔癌前病变
表达高水平PDPN的病变(例如白斑病)成为癌症的可能性是正常的几倍
而不是不表达PDPN的病变。此外,PDPN已被确定为免疫细胞检查点
辅阻遏物事实上,PDPN已成为功能相关的生物标志物和化疗靶点
可以用来检测和治疗口腔癌。我们的理论基础是钙粘蛋白连接是
通常在转化细胞之间被破坏,而PDPN表达增强。
PDPN抗体和怀槐种子凝集素(MASL)有效地靶向PDPN,以减少PDPN的表达。
OSCC细胞运动性和活力。此外,MASL是无毒的,并且可以口服给药以抑制肿瘤
在临床前研究中没有显著的副作用。我们假设钙粘蛋白
介导接触正常化以抑制PDPN表达,并且PDPN可以用作功能性调节剂。
协同抑制肿瘤细胞生长和增强抗癌免疫相关化疗靶点
反应我们提出了三个具体目标来检验这一假设。
在目标1中,我们将确定非转化细胞是否需要钙粘蛋白来使形态正常化,
相邻Src转化细胞和OSCC细胞的生长、运动性、Wnt信号传导和PDPN表达。在目标2中,
我们将确定PDPN信号是否能使Src转化的成纤维细胞和OSCC细胞抑制生长,
由邻近的非转化细胞控制。在目标3中,我们将确定MASL是否可以针对PDPN进行扩增
在FDA批准的1期试验中,宿主免疫应答与其抑制OSCC细胞生长的能力一致
口腔癌患者的人体临床试验。
这个项目将使研究生和医学生接触到分子和细胞生物学的基础研究
阐明接触正常化背后的基本机制。这项工作将提高我们的能力,
检测,预防和治疗口腔癌,以及其他由PDPN信号驱动的癌症。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Independent effects of Src kinase and podoplanin on anchorage independent cell growth and migration.
- DOI:10.1002/mc.23410
- 发表时间:2022-07
- 期刊:
- 影响因子:4.6
- 作者:
- 通讯作者:
Maackia amurensis seed lectin (MASL) ameliorates articular cartilage destruction and increases movement velocity of mice with TNFα induced rheumatoid arthritis.
- DOI:10.1016/j.bbrep.2022.101341
- 发表时间:2022-12
- 期刊:
- 影响因子:2.7
- 作者:Hamilton, Kelly L.;Greenspan, Amanda A.;Shienbaum, Alan J.;Fischer, Bradford D.;Bottaro, Andrea;Goldberg, Gary S.
- 通讯作者:Goldberg, Gary S.
Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells.
- DOI:10.1186/s12964-021-00817-9
- 发表时间:2022-02-17
- 期刊:
- 影响因子:0
- 作者:Sheehan SA;Retzbach EP;Shen Y;Krishnan H;Goldberg GS
- 通讯作者:Goldberg GS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY S GOLDBERG其他文献
GARY S GOLDBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY S GOLDBERG', 18)}}的其他基金
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
- 批准号:
6917827 - 财政年份:2005
- 资助金额:
$ 48.3万 - 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
- 批准号:
7109343 - 财政年份:2005
- 资助金额:
$ 48.3万 - 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
- 批准号:
6785502 - 财政年份:2003
- 资助金额:
$ 48.3万 - 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
- 批准号:
7073631 - 财政年份:2003
- 资助金额:
$ 48.3万 - 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
- 批准号:
6923578 - 财政年份:2003
- 资助金额:
$ 48.3万 - 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
- 批准号:
6576040 - 财政年份:2003
- 资助金额:
$ 48.3万 - 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
- 批准号:
6780978 - 财政年份:2002
- 资助金额:
$ 48.3万 - 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
- 批准号:
6540944 - 财政年份:2002
- 资助金额:
$ 48.3万 - 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
- 批准号:
6605626 - 财政年份:2002
- 资助金额:
$ 48.3万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别: